Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Jeil Pharma Holdings Inc. is a prominent entity in the pharmaceutical sector, recognized for its comprehensive range of healthcare products and solutions. Primarily, the company focuses on the development, manufacturing, and distribution of pharmaceuticals and medical supplies. This includes prescription medications, over-the-counter drugs, and various healthcare products that cater to a wide array of medical needs. Jeil Pharma Holdings plays a significant role in the healthcare industry by advancing medical research and enhancing public health outcomes. With its robust product portfolio, the company impacts both local and global markets by addressing critical therapeutic areas such as cardiology, neurology, and infectious diseases. The strategic position of Jeil Pharma Holdings in the market is further bolstered by its commitment to quality, innovation, and compliance with global healthcare standards. By leveraging advanced technologies and expanding its research capabilities, the company aims to contribute significantly to the progress of medical science and improve accessibility to essential healthcare products.
₩6,710.00
+₩110.00 (+1.67%)
Live · 11:10 AM
Operating margin is thin at 5.93%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue declined 15.7% YoY. The question is whether this is cyclical or a structural shift.
Negative free cash flow of -₩8.94B. The business is consuming cash, not generating it.
5.4x earnings, 72.6x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
₩625.97B
▼ -15.7% YoY
Net Income (TTM)
₩34.52B
▲ +152.2% YoY
Op. Margin
5.68%
▲ +7.4pp YoY
ROIC
5.58%
▲ +7.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
₩1.41B
▼ -285.1% YoY
Op. Cash Flow (TTM)
₩74.48B
▲ +3250.9% YoY
Net Debt
₩88.06B
Cash & Equiv.
₩79.31B
3Y CAGR: -6.0%
Continue Research
At a P/E of 5.4 and a price-to-free-cash-flow of 72.6, Jeil Pharma Holdings (002620.XKRX) trades above a two-stage DCF intrinsic value of about KRW -3,449.35 per share, so at KRW 6,710.00 the stock looks overvalued (151.4% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Jeil Pharma Holdings scores 48/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 0.2%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about KRW -3,449.35 per share for 002620.XKRX, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around KRW -2,587.01. At today's KRW 6,710.00, that puts the stock about 151.4% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Jeil Pharma Holdings scores 48 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 5.7% operating margin and a 5.6% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Jeil Pharma Holdings pays a regular dividend of about KRW 11.96 per share per year (typically in quarterly installments), a yield of roughly 0.2% at the current price. That is a payout ratio of about 0.5% of earnings, so the dividend is amply covered by earnings. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For 002620.XKRX's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. 002620.XKRX currently trades above its estimated intrinsic value and scores 48/100 on quality (mixed). It also yields about 0.2%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.